| Dec'19 | Dec'18 | Dec'17 | Dec'16 | |||
|---|---|---|---|---|---|---|
Revenue | ||||||
3,837 | 2,444 | - | - | |||
Revenue | ||||||
- | - | 1,558 | 1,103 | |||
Cost of revenue | ||||||
917 | 728 | 505 | 282 | |||
Gross profit | ||||||
2,920 | 1,715 | 1,053 | 821 | |||
Operating expenses: | ||||||
Research and development | ||||||
2,160 | 1,838 | 1,751 | 1,120 | |||
Selling, general and administrative | ||||||
11,554 | 10,405 | 5,849 | 2,975 | |||
Total operating expenses | ||||||
13,715 | 12,244 | 7,601 | 4,096 | |||
Loss from operations | ||||||
-10,795 | -10,528 | -6,548 | -3,275 | |||
Other expense (income) | ||||||
Change in fair value of derivative liabilities | ||||||
-194 | -36 | 116 | - | |||
Debt discount on convertible notes | ||||||
- | - | 5,172 | - | |||
Interest (income) expense and other expense, net | ||||||
-1 | -175 | -358 | -342 | |||
Non-cash interest expense, debt discount | ||||||
113 | - | - | - | |||
Loss on extinguishment of debt | ||||||
- | - | -135 | - | |||
Total other expense (income) | ||||||
81 | 211 | -5,549 | -342 | |||
Net loss | ||||||
-10,713 | -10,316 | -12,097 | -3,617 | |||
Deemed dividend – accreted preferred stock | ||||||
- | - | 274 | 108 | |||
Cumulative dividend to Series B-1 preferred stockholders | ||||||
- | - | 287 | 658 | |||
Net loss attributable to common stockholders | ||||||
- | - | -12,659 | -4,384 | |||
Weighted average number of common shares outstanding: | ||||||
Basic and diluted | ||||||
553 | 409 | 4,317 | 1,060 | |||
Net loss per share attributable to common stockholders | ||||||
Basic and diluted | ||||||
-19.35 | -25.18 | -2.93 | -4.13 | |||